Study guide

4.1 PSA Kinetics, Biomarkers & Risk Assessment

FEBU Part 1 Written European Board of Urology

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice

2 Chapter 2: Genitourinary Anatomy & Renal Physiology

2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance

3 Chapter 3: Urological Pharmacology & Diagnostic Imaging

3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine

4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification

4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging

5 Chapter 5: Prostate Cancer: Localized & Advanced Management

5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)

6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)

6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy

7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)

8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms

8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas

9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer

9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy

10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms

10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO

11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology

11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation

12 Chapter 12: Urolithiasis: Evaluation & Medical Management

12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy

13 Chapter 13: Endourology & Interventional Stone Management

13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety

14 Chapter 14: Infections, Andrology & Male Infertility

14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery

15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation

15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation

4.1 PSA Kinetics, Biomarkers & Risk Assessment

Key Takeaways Explain This Topic AI

EAU risk-adapted early PSA testing starts at age 50 generally, 45 for men of African descent or a family history of prostate cancer before 60, and 40 for BRCA2 carriers, after informed discussion and life-expectancy assessment.

PSA is prostate-specific, not cancer-specific. A lower free-to-total ratio and higher PSA density increase suspicion, but biopsy decisions combine repeat PSA, MRI, family history and other clinical risk factors.

PSA velocity or doubling time alone should not trigger a diagnostic biopsy or a treatment change during active surveillance. Kinetics can prompt reassessment and help stratify recurrence after treatment.

PHI and 4Kscore can improve risk prediction before biopsy. Additional biomarkers are an optional EAU pathway tool; the added value of urine tests alongside upfront MRI or after a negative biopsy remains uncertain.

An abnormal DRE warrants further investigation even with a low PSA: usually MRI, or direct biopsy when extracapsular disease is suspected. Low PSA does not exclude cancer.

Last updated: November 2026

PSA Kinetics, Biomarkers & Risk Assessment

Prostate cancer (PCa) represents the most frequently diagnosed non-cutaneous malignancy in European men and ranks as the third leading cancer-related cause of death in European men. The primary diagnostic challenge in modern uro-oncology is not merely detecting cancer, but accurately discriminating between indolent, slow-growing tumors that will never cause clinical harm and aggressive, clinically significant prostate cancers (csPCa) that require timely definitive intervention.

Achieving this balance requires an understanding of prostate cancer epidemiology, genetic predisposition, prostate-specific antigen (PSA) biology, and advanced secondary biomarkers endorsed by the European Association of Urology (EAU) Guidelines.

Epidemiology and Etiological Risk Factors

The development of prostate cancer is driven by a complex interplay of non-modifiable demographic factors and germline genetics:

Age : The incidence of prostate cancer rises steeply after the age of 50. Autopsy studies reveal microscopic, latent foci of adenocarcinoma in over 30% of men in their 50s and up to 60–70% of men aged 80 years or older.

Ethnic Ancestry : Men of African ancestry exhibit the highest incidence and mortality rates globally, presenting on average at an earlier age with higher-grade disease and higher PSA levels at presentation, driven by a combination of biological, genomic, and healthcare disparity factors. Conversely, men of Asian descent historically demonstrate the lowest incidence rates.

Family History : An affected first-degree relative approximately doubles risk; multiple affected relatives and early diagnoses increase suspicion of inherited susceptibility. EAU defines hereditary prostate cancer as ≥3 cases in one family, disease in three successive generations, or ≥2 cases diagnosed before 55. Familial clustering alone does not necessarily meet that definition.

Germline Genetic Alterations :

BRCA2 : The most clinically impactful genetic mutation in prostate cancer. Pathogenic BRCA2 variants confer several-fold increased risk, especially for early-onset disease; a UK study estimated an 8.6-fold risk by age 65. Furthermore, BRCA2 -mutated tumors demonstrate an aggressive biological phenotype characterized by higher ISUP Grade Groups, early extracapsular extension, lymph node involvement, visceral metastasis, and significantly reduced cancer-specific survival.

BRCA1 : Confers a more modest risk elevation (~3.8-fold increase in men aged <= 65 years).

Mismatch Repair (MMR) Genes / Lynch Syndrome : Pathogenic germline variants in MSH2 , MSH6 , MLH1 , or PMS2 confer an estimated 2- to 3-fold elevated risk of aggressive prostate adenocarcinoma.

Other Susceptibility Genes : ATM and CHEK2 participate in DNA-damage responses. HOXB13 encodes a homeobox transcription factor; its G84E variant is also associated with inherited prostate-cancer susceptibility.

EAU Guidelines on Early Detection & Risk-Adapted Screening

Mass, unselected, population-wide PSA screening remains unendorsed across Europe due to the substantial risks of overdiagnosis (detecting clinically insignificant tumors) and subsequent overtreatment (urinary incontinence, erectile dysfunction). However, landmark randomized trials—notably the European Randomized Study of Screening for Prostate Cancer (ERSPC)—demonstrated a persistent 20% relative reduction in prostate cancer-specific mortality at 16 years of follow-up in screened cohorts.

To capture the survival benefit of early detection while minimizing harm, the EAU Guidelines advocate for an individualized, risk-adapted early detection strategy for well-informed men with a life expectancy of at least 15 years:

Informed Consent & Counseling : Men requesting early detection must receive balanced counseling regarding potential benefits (reduced metastases and mortality) and harms (false-positive biopsies, biopsy sepsis, overdiagnosis of indolent disease).

Target Populations for Baseline PSA Testing :

Age 50 years : All well-informed men in the general population.

Age 45 years : Men of African descent or with a family history of prostate cancer diagnosed before 60.

Age 40 years : Men carrying pathogenic BRCA2 germline mutations (supported by findings from the prospective IMPACT trial).

Baseline PSA Stratification & Rescreening Intervals :

Initially increased risk: PSA >1 ng/mL at age 40 or >2 ng/mL at age 60 supports a two-year retesting interval.

Lower initial risk: Retesting can be postponed for up to eight years. Baseline PSA predicts long-term risk; choose the interval with age, family history and overall health.

Stopping Criteria : PSA testing should be discontinued in asymptomatic men whose life expectancy is less than 10 to 15 years, as screen-detected indolent or intermediate-risk tumors are highly unlikely to impact survival within that timeframe.

Prostate-Specific Antigen (PSA) and Derivatives

Total PSA is a 33-kDa single-chain glycoprotein enzyme (human kallikrein-related peptidase 3, KLK3 ) synthesized almost exclusively by the secretory columnar epithelial cells of the prostate. Its physiological role is to liquefy the seminal coagulum by cleaving semenogelins. PSA is organ-specific, not cancer-specific .

Serum PSA concentrations can be elevated by non-malignant conditions, including benign prostatic hyperplasia (BPH; generating ~0.3 ng/mL per gram of adenoma), acute or chronic bacterial prostatitis, urinary tract infections, acute urinary retention, transurethral catheterization or instrumentation, recent prostate biopsy (elevations persist for 4–6 weeks), vigorous cycling, and recent ejaculation (transient mild elevations lasting 48 hours). To avoid false-positive elevations, EAU recommends repeating an initially elevated PSA of 3–10 ng/mL in an asymptomatic man with normal DRE , typically after four weeks in the same laboratory/assay and without UTI, ejaculation or manipulation. A suspicious DRE or other high-risk presentation needs its own diagnostic pathway.

Free-to-Total PSA Ratio (%fPSA)

In human serum, PSA circulates in two distinct physical states: free PSA (enzymatically inactive, unbound, representing 5–35% of total serum PSA) and complexed PSA (bound irreversibly to protease inhibitors, predominantly alpha-1-antichymotrypsin [ACT] and alpha-2-macroglobulin). Prostate cancer tissue predominantly synthesizes PSA that readily complexes with ACT, resulting in a decreased proportion of circulating free PSA compared to benign tissue.

In patients presenting with a total PSA in the diagnostic grey zone (4.0 to 10.0 ng/mL) and a non-suspicious digital rectal examination:

Free/total ratio <0.15 (15%) : Raises suspicion compared with a higher ratio; it does not establish cancer or its grade.

Ratio >0.25 (25%) : Suggests lower risk, but does not rule out cancer. Integrate MRI, PSA density, age and family history rather than assigning a universal cancer probability or biopsy decision to either cutoff.

PSA Density (PSAD)

PSA Density represents the ratio of total serum PSA concentration (ng/mL) to prostate gland volume (measured in cubic centimeters or milliliters via transrectal ultrasound [TRUS] or magnetic resonance imaging [MRI]):

PSAD = Total PSA (ng/mL) Prostate Volume (cc) \text{PSAD} = \frac{\text{Total PSA (ng/mL)}}{\text{Prostate Volume (cc)}} PSAD = Prostate Volume (cc) Total PSA (ng/mL) ​

PSAD corrects for the volumetric contribution of benign transitional zone hyperplasia. A commonly used risk threshold is 0.15 ng/mL/cc , interpreted with the MRI category and other findings:

PSAD > 0.15 ng/mL/cc : Significantly increases the likelihood of clinically significant prostate cancer. It serves as a major deciding factor for performing biopsy, particularly in men with equivocal multiparametric MRI findings (PI-RADS 3) or those being monitored on active surveillance.

PSAD <0.10 ng/mL/cc : Suggests lower risk of clinically significant cancer; it does not prove that BPH explains the PSA or exclude malignancy.

PSA Velocity (PSAV) and Doubling Time (PSADT)

PSA Velocity (PSAV) : Reflects the absolute rate of PSA increase over time (ng/mL/year), requiring a minimum of three longitudinal measurements obtained across at least 12 to 18 months. Historically, a PSAV > 0.75 ng/mL/year was considered suspicious.

PSA Doubling Time (PSADT) : Measures the exponential time required for the serum PSA level to double.

Important

Do not use PSA kinetics alone to decide on diagnostic biopsy. Fluctuations from benign disease limit specificity. During active surveillance , a concerning trend prompts MRI and/or repeat biopsy rather than treatment based on PSA alone. After definitive treatment, PSA kinetics contribute to recurrence risk assessment and management.

Novel Pre-Biopsy Blood and Urine Biomarkers

To improve diagnostic accuracy and reduce the burden of negative prostate biopsies in men with total PSA levels between 2.0 and 10.0 ng/mL, several molecular reflex biomarkers have been developed and validated:

Blood-Based Biomarkers

Prostate Health Index (phi) : Combines total PSA, free PSA, and the precursor isoform [-2]proPSA into a single algorithmic index: phi = [ − 2 ] proPSA Free PSA × Total PSA \text{phi} = \frac{[-2]\text{proPSA}}{\text{Free PSA}} \times \sqrt{\text{Total PSA}} phi = Free PSA [ − 2 ] proPSA ​ × Total PSA ​ The [-2]proPSA isoform is preferentially expressed in prostate cancer tissue. Higher PHI scores indicate greater risk of clinically significant cancer; cutoff performance depends on the population and desired sensitivity. In one prospective study, a 28.6 cutoff at 90% sensitivity could spare 30.1% of unnecessary biopsies. This is a trade-off, not a guarantee that significant cancer will never be missed.

4Kscore Test : A commercially available blood test that measures four kallikrein markers in plasma—total PSA, free PSA, intact PSA, and human kallikrein 2 (hK2)—and combines them with patient age, digital rectal examination findings, and prior biopsy history using a proprietary algorithm. The test generates an individualized percentage risk (0–100%) of finding high-grade (Gleason score >= 7 / ISUP Grade Group >= 2) cancer on biopsy.

Urine-Based Biomarkers

SelectMDx : A non-invasive urine test performed on post-DRE first-void urine. It measures the mRNA expression levels of two biomarker genes ( HOXC6 and DLX1 ) that are overexpressed in clinically significant prostate cancer, combining these molecular signals with clinical risk factors (age, PSA, PSAD, DRE status, family history). SelectMDx provides an individualized probability of finding ISUP >= 2 cancer on biopsy. Its predictive values depend on the tested population and threshold. EAU considers its added clinical value in the upfront-MRI pathway unclear; a negative result is not a guarantee that biopsy can safely be omitted.

PCA3 (Prostate Cancer Antigen 3) : A prostate-specific, non-coding mRNA transcript that is overexpressed 60- to 100-fold in prostate adenocarcinoma compared to adjacent normal or hyperplastic tissue. Measured in first-catch post-DRE urine, the PCA3 score is calculated as the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. A PCA3 score > 35 indicates elevated cancer probability. PCA3 has been studied and used in the repeat-biopsy setting , but EAU considers its clinical utility for current biopsy decisions unclear.

ExoDx Prostate (IntelliScore - EPI) : A liquid biopsy assay measuring exosomal RNA levels of three genes ( ERG , PCA3 , and SPDEF ) in first-void urine collected without requiring a prior digital rectal examination . The 15.6 threshold has been studied for risk stratification in biopsy-naive men aged ≥50 with PSA 2–10 ng/mL; it is not diagnostic. EAU currently considers ExoDx investigational.

Digital Rectal Examination (DRE)

Digital rectal examination evaluates the posterior and posterolateral surfaces of the peripheral zone, which accounts for approximately 70% of prostate cancers. A normal prostate feels smooth, symmetrical, and fibroelastic, with a preserved central sulcus.

Clinical Findings and Pitfalls

Suspicious Findings : Palpable induration, discrete stone-hard nodules, asymmetrical lobar enlargement, obliteration of the median sulcus, or fixation to the pelvic sidewalls.

Diagnostic Limitations : DRE has low sensitivity (approximately 50–60%) for early-stage organ-confined tumors. Tumors situated in the anterior peripheral zone, the anterior fibromuscular stroma, or the transition zone are anatomically inaccessible to digital palpation.

Guideline Pathway : An abnormal DRE warrants MRI, or direct biopsy if extracapsular disease is suspected , even when PSA is below a conventional cutoff. EAU reports that about 18% of cancers are detected by suspicious DRE alone, irrespective of PSA. DRE findings also contribute to clinical staging; integrate the examination with PSA, MRI and the clinical context when deciding on tissue sampling.

Clinical Prostate Biomarkers Comparison

Biomarker Specimen Target Analytes / Components Diagnostic Cutoff / Interpretation EAU Guideline Status

Total PSA (tPSA) Serum Free and complexed human kallikrein 3 Continuous risk marker; no universal normal/abnormal cutoff Primary test in an informed, risk-adapted early-detection pathway

Free-to-Total PSA (%fPSA) Serum Ratio of unbound PSA to total PSA Lower ratio raises suspicion; >0.25 suggests lower risk Adjunct risk information; not a stand-alone biopsy rule

PSA Density (PSAD) Serum / Ultrasound or MRI Total PSA divided by total prostate volume Higher density increases risk; 0.15 is a common threshold Interpret with MRI category and clinical risk

Prostate Health Index (phi) Serum Total PSA, free PSA, [-2]proPSA Higher score indicates higher risk; threshold-dependent performance Optional additional biomarker; improves prediction over f/t PSA

4Kscore Plasma / Serum tPSA, fPSA, intact PSA, hK2 + age, DRE, prior biopsy Probability score (0–100%) for ISUP >= 2 cancer Optional additional biomarker; improves csPCa risk prediction

SelectMDx Post-DRE Urine mRNA expression of HOXC6 and DLX1 + clinical model Algorithmic risk estimate; NPV depends on population Added value with upfront MRI remains unclear

PCA3 Post-DRE Urine Non-coding PCA3 mRNA to PSA mRNA ratio Score > 35 indicates elevated cancer probability Studied after negative biopsy; current clinical utility unclear

ExoDx Prostate (EPI) Urine (No DRE) Exosomal mRNA of ERG , PCA3 , and SPDEF Studied 15.6 threshold estimates ISUP ≥2 risk Investigational under current EAU guidance